Why pharmacists are concerned about the safety of biosimilars August 10, 2016 By Christine Blank Pharmacists and other healthcare professionals are looking to the FDA for more guidance on biosimilars and interchangeability with their reference products. Biosimilars for cancer treatment on the U.S. horizon August 10, 2016 By Randy Dotinga Cancer treatments are expected to dominate much of the first wave of biosimilars in the U.S. This Q&A discussion looks at some of the questions pharmacists have about use of biosimilars in cancer treatment. Biosimilar: Coming to a pharmacy near you Biosimilars are the future of pharmacy. When they hit community pharmacy, issues that have been important in specialty settings are going to explode. Biosimilar drugs appear comparable to brand-name counterparts August 08, 2016 By Tracey Walker Systematic review provides comprehensive first look at TNF-alpha biosimilar treatments. New bill aims to support generic, biosimilar drug competition July 06, 2016 By Christine Blank The CREATES Act came about because some pharmaceutical manufacturers are misusing the REMS program to prevent generic drug development. Survey finds stakeholders lack understanding of biosimilars June 27, 2016 By Tracey Walker It is important to look at how the introduction of biosimilars in the United States may affect your business and your stakeholders and plan for those changes accordingly, according to a new report. Biosimilars uptake may lag for cancer patients, physicians June 09, 2016 By Bryant Furlow Biosimilars will have a significant impact on cancer treatment, with the potential to drive cost savings, but will patients and providers be accepting? Arizona passes pharmacy biosimilar law June 02, 2016 By Christine Blank Arizona recently joined around 20 other states by passing a law allowing pharmacists to substitute certain interchangeable biosimilar drugs for brand name drugs. The biosimilar balance: More options, lower costs The fly in the ointment: CMS' current plan for HCPCS codes is a real buzz kill. Predictions for the future of high-cost specialty drugs April 25, 2016 By Mari Edlin IMS Health expert predicts future drug spending trends and ways to curb rising costs at the AMCP 2016 conference.